Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.
Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.
Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Eric Morand, MD, PhD, explains why rheumatologists failing in lupus while succeeding so spectacularly in diseases like rheumatoid arthritis and what needs to change.
Treatment of the osteoarthritis has been at a standstill, with short-term pain management with steroid injections considered standard care. However, a promising new therapeutic approach may help to sustain pain relief over time.
Rheumatology Network sat down with Mehret Birru Talabi, MD, PhD, to discuss the recent study published in ACR Open Rheumatology entitled, “Tough choices: Exploring medication decision-making during pregnancy and lactation among women with inflammatory arthritis.”
Jeffrey Stark, MD, discusses the statement UCB issued endorsing the creation of a new sub-category (M.45A) for non-radiographical axial spondyloarthritis (nr-axSpA).
In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.
Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.
Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."
Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.
Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.
An expert rheumatologist shares key insights into common causes, typical presentation, and differential diagnosis of systemic lupus erythematous (SLE) and idiopathic inflammatory myopathies.
Rheumatology Network sat down with Pedro Machado, MD, PhD, to discuss his EULAR 2021 presentation entitled, “COVID-19 vaccine safety in patients with rheumatic and musculoskeletal disease.”
Kostas N. Botsoglou, MD, provides an overview of systemic autoimmune rheumatic diseases (SARDs) or connective tissue diseases by discussing their overall characteristics, common comorbidities, and impact on patient quality of life.
Roy Fleischmann, MD, discusses his presentations for EULAR 2021, which include topics about the side effects of JAK inhibitors, disease activity measures of methotrexate withdrawal among patients with rheumatoid arthritis, and the long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis.
Neil Solomons, MD, sits down to discuss his latest study, entitled “Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet,” which will be presented at EULAR 2021.
As a part of our EULAR 2021 coverage, Rheumatology Network sat down with John Botson, MD, RPh, CCD, to discuss why patients with uncontrolled gout are significantly burdened with systemic co-morbid disease, why gout is more prevalent and severe in patients who have received kidney transplants, and why such few studies have been published on the use of pegloticase in organ transplant patients.
Rheumatology Network interviewed Laura Coates, MBChB, MRCP, PhD, to discuss what her recent study adds to existing psoriatic arthritis (PsA) research, what some of the key factors are that impact a patient’s opinion of remission, and the clinical significance.
Rheumatology Network sat down with Daniel Hernandez, MD, and Shilpa Venkatachalam, PhD, MPH, of CreakyJoints to highlight health disparities in marginalized communities and introduce their exciting new venture, CreakyJoints Espanol.
This week, Rheumatology Network sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”
Recommendations for supporting patients with psoriatic arthritis in the primary care setting and guidance on referring patients to a specialist.
Circumstances that may warrant a switch in therapy to either a similar drug or a drug of a different class.
Currently available non-biologic and biologic therapies used to treat psoriatic arthritis and guidance regarding proper treatment selection and use.
Goals of therapy and considerations that need to be factored into treatment decisions for patients with psoriatic arthritis.
An overview of the clinical manifestations of psoriatic arthritis and recommendations for properly assessing patient symptoms when measuring disease severity.
Strategies that can help clinicians assess patients with psoriatic arthritis for signs of disease progression.
The impact of psoriatic arthritis on patients’ quality of life and importance of an early, accurate diagnosis.
Rheumatology Network sat down with Rebecca Manno, MD, MHS, to discuss the American College of Rheumatology State of the Art (ACR SOTA) Clinical Symposium, which ran from April 9-11.
As a part of our partnership with CreakyJoints, Rheumatology Network sat down with Lauren Gelman, Director of Editorial Services, for the Global Healthy Living Foundation. CreakyJoints is a support, education, advocacy, and research organization for people living with arthritis and rheumatic disease.